Dr. Wen Shuhao Appointed to MIT Visiting Committee, Becoming Youngest Member in Chemistry Division

Blog details
2 min read
Share this:

Dr. Shuhao Wen, Co-founder and Chairman of XtalPi (2228.HK), has joined MIT’s Visiting Committees—a 149-year-old advisory body—as the youngest member and sole representative from mainland China in its Chemistry Division. Over the next four years, Dr. Wen will advise MIT on integrating foundational research with emerging technologies and talent development.

MIT’s Legacy of Innovation
MIT, renowned for its motto Mens et Manus (“Mind and Hand”), leads global innovation in chemistry, computer science, and entrepreneurship. Its Visiting Committees, established in 1875, have shaped academic programs, research funding, and graduate education for over a century.

2024 Chemistry Division Members
The 22-member committee includes:

  • David A. Tirrell (Provost, Caltech)  
  • Jeannette M. Wing (VP of Research, Columbia University)
  • Squire Booker (Eberly Family Chair, Penn State)
  • Melissa J. Moore (CSO, Moderna)
  • Rebecca Ruck (Executive Director, Merck)

A Shared Vision for Innovation
XtalPi’s founders, who met at MIT, embody the institute’s entrepreneurial spirit. MIT Chemistry Chair Prof. Troy Van Voorhis praised XtalPi’s AI-driven labs: “XtalPi is a perfect example of the kind of impact MIT wants to have in supporting young scientists with big ideas who want to change the world.” Dr. Wen stated: “I aim to strengthen academia-industry collaboration, leveraging MIT’s expertise in innovation translation to invigorate China’s scientific ecosystem while contributing XtalPi’s technical insights to MIT’s research programs.”

Your next success starts here

Recommended articles

XtalPi and Baicheng Medicine Announce Strategic Collaboration to Advance Innovative Drug Development
XtalPi Leadership Visits China Merchants Group to Explore Strategic Collaboration in AI-Driven Innovation
XtalPi Announces Milestone Achievement in Collaboration with PharmaEngine on Next-Generation PRMT5 Inhibitor PEP08
Signet Therapeutics, Incubated by XtalPi, Nominated for 2025 Prix Galien USA Best Biotechnology Award for First-in-Class Diffuse Gastric Cancer Drug SIGX1094R

XtalPi Newsletter